Receptor autoimmunity: diagnostic and therapeutic implications

[1]  R. Herbst,et al.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture , 2019, Cells.

[2]  R. Murray,et al.  Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study , 2019, Thyroid : official journal of the American Thyroid Association.

[3]  F. Barrantes,et al.  Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets. , 2019, ACS chemical neuroscience.

[4]  M. Ungerer,et al.  Therapeutic Effects of Short Cyclic and Combined Epitope Peptides in a Long-Term Model of Graves' Disease and Orbitopathy. , 2019, Thyroid : official journal of the American Thyroid Association.

[5]  R. Latif,et al.  Editorial: TSH Receptor and Autoimmunity , 2019, Front. Endocrinol..

[6]  R. Latif,et al.  Antigenic “Hot- Spots” on the TSH Receptor Hinge Region , 2019, Front. Endocrinol..

[7]  E. Pocheć,et al.  Glycosylation of thyroid-stimulating hormone receptor. , 2019, Endokrynologia Polska.

[8]  B. Rapoport,et al.  Reflections on Thyroid Autoimmunity: A Personal Overview from the Past into the Future , 2018, Hormone and Metabolic Research.

[9]  L. Wollmuth,et al.  Structure, function, and allosteric modulation of NMDA receptors , 2018, The Journal of general physiology.

[10]  J. Shang,et al.  The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy , 2018, Medicine.

[11]  N. Silvestri,et al.  Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. , 2018, Neurologic clinics.

[12]  P. Fu,et al.  Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis , 2018, Front. Med..

[13]  H. Ehrenreich.  Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease , 2018, Current opinion in neurology.

[14]  M. Rosenfeld,et al.  Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor , 2018, Neurology.

[15]  R. Tozzoli.  The increasing clinical relevance of thyroid-stimulating hormone receptor autoantibodies and the concurrent evolution of assay methods in autoimmune hyperthyroidism , 2018 .

[16]  D. Ricci,et al.  Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves’ disease , 2018, Autoimmunity Highlights.

[17]  K. O’Connor,et al.  B cells in the pathophysiology of myasthenia gravis , 2018, Muscle & nerve.

[18]  F. Pieruzzi,et al.  Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases , 2018, Journal of Nephrology.

[19]  V. Steen,et al.  Role of anti-receptor autoantibodies in pathophysiology of scleroderma. , 2017, Autoimmunity reviews.

[20]  A. Pini,et al.  Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies , 2017, Neurological Sciences.

[21]  Jie Zhu,et al.  Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis , 2017, Mediators of inflammation.

[22]  A. Verkman,et al.  Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..

[23]  Asha Hesarghatta Shyamasunder,et al.  Measuring TSH receptor antibody to influence treatment choices in Graves’ disease , 2017, Clinical endocrinology.

[24]  G. Han,et al.  Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications , 2017, eLife.

[25]  Catherine L. Worth,et al.  Structural–Functional Features of the Thyrotropin Receptor: A Class A G-Protein-Coupled Receptor at Work , 2017, Front. Endocrinol..

[26]  G. Wallukat,et al.  Cardiomyopathy - An approach to the autoimmune background. , 2017, Autoimmunity reviews.

[27]  K. Nath,et al.  A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[28]  E. Gouaux,et al.  Structure and symmetry inform gating principles of ionotropic glutamate receptors , 2017, Neuropharmacology.

[29]  L. Giovanella,et al.  Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease , 2017, Clinical chemistry and laboratory medicine.

[30]  N. Bizzaro,et al.  Challenges in the Standardization of Autoantibody Testing: a Comprehensive Review , 2017, Clinical Reviews in Allergy & Immunology.

[31]  R. Núñez Miguel,et al.  Structure and activation of the TSH receptor transmembrane domain , 2016, Autoimmunity Highlights.

[32]  E. Disse,et al.  Antibody-Mediated Insulin Resistance: When Insulin and Insulin Receptor Act as Autoantigens in Humans. , 2016, Canadian journal of diabetes.

[33]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[34]  J. Seckl,et al.  Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse. , 2016, Thyroid : official journal of the American Thyroid Association.

[35]  M. Saji,et al.  Bioassays for TSH Receptor Autoantibodies, from FRTL-5 Cells to TSH Receptor–LH/CG Receptor Chimeras: The Contribution of Leonard D. Kohn , 2016, Front. Endocrinol..

[36]  A. Vincent,et al.  Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms , 2016, F1000Research.

[37]  D. Sandler,et al.  Early Life Factors Associated with Adult-Onset Systemic Lupus Erythematosus in Women , 2016, Front. Immunol..

[38]  A. Zwinderman,et al.  Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. , 2016, The Journal of clinical endocrinology and metabolism.

[39]  Terry J. Smith,et al.  Graves' Disease. , 2016, The New England journal of medicine.

[40]  L. Truong,et al.  Enigma (partially) resolved: phospholipase A2 receptor is the cause of "idiopathic" membranous glomerulonephritis. , 2015, American journal of physiology. Renal physiology.

[41]  T. Davies,et al.  Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies , 2015 .

[42]  Huhai Zhang,et al.  Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis , 2015, Scientific Reports.

[43]  J. Dalmau,et al.  Autoimmune encephalopathies , 2015, Annals of the New York Academy of Sciences.

[44]  P. D. Olivo,et al.  Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. , 2015, Thyroid : official journal of the American Thyroid Association.

[45]  T. Jowitt,et al.  Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[46]  A. Vincent,et al.  Autoimmune encephalopathies. , 2015, Pediatric clinics of North America.

[47]  F. Boege,et al.  Diagnostic and therapeutic aspects of β1-adrenergic receptor autoantibodies in human heart disease. , 2014, Autoimmunity reviews.

[48]  M. Fritzler,et al.  Antiphospholipase A2 Receptor Autoantibodies: A Comparison of Three Different Immunoassays for the Diagnosis of Idiopathic Membranous Nephropathy , 2014, Journal of immunology research.

[49]  R. Balice-Gordon,et al.  Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study , 2014, The Lancet Neurology.

[50]  J. Wetzels,et al.  Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[51]  G. Barbesino,et al.  Clinical Utility of TSH Receptor Antibodies , 2013 .

[52]  D. Giavarina,et al.  TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. , 2012, Autoimmunity reviews.

[53]  U. Panzer,et al.  An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[55]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[56]  R. Glassock.  The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[57]  H. Bürgi.  Thyroid Eye Disease: A Historical Perspective , 2009, Orbit.

[58]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[59]  M. Soos,et al.  Autoimmune Forms of Hypoglycemia , 2009, Medicine.

[60]  Josep Dalmau,et al.  Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma , 2007, Annals of neurology.

[61]  L. Wartofsky,et al.  Graves' disease. , 2007, The Journal of clinical endocrinology and metabolism.

[62]  N. Unwin,et al.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution. , 2005, Journal of molecular biology.

[63]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[64]  Y. Rajabally,et al.  Hypokalemic periodic paralysis associated with malignant hyperthermia , 2002, Muscle & nerve.

[65]  J. Lindstrom.  Acetylcholine receptors and myasthenia , 2000, Muscle & nerve.

[66]  C Bona,et al.  Defining criteria for autoimmune diseases (Witebsky's postulates revisited) , 1993, Immunology today.

[67]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[68]  D. Adams.  Long-acting thyroid stimulator: how receptor autoimmunity was discovered. , 1988, Autoimmunity.

[69]  A. Pestronk,et al.  Myasthenia gravis: passive transfer from man to mouse , 1975, Science.

[70]  J. Patrick,et al.  Autoimmune Response to Acetylcholine Receptor , 1973, Science.

[71]  J. Simpson.  Myasthenia Gravis: A New Hypothesis , 1960 .